Voreloxin hydrochloride
CAS No. 175519-16-1
Voreloxin hydrochloride( Vosaroxin | SNS-595 hydrochloride )
Catalog No. M23789 CAS No. 175519-16-1
Voreloxin hydrochloride is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 33 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 98 | In Stock |
|
| 25MG | 158 | In Stock |
|
| 50MG | 256 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVoreloxin hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionVoreloxin hydrochloride is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity.
-
DescriptionVoreloxin hydrochloride is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity.
-
In VitroVoreloxin Hydrochloride is a first-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis. Voreloxin (0.1-20 μM) inhibits topoisomerase II activity and induces site-selective DNA DSB in CCRF-CEM cells. Voreloxin (0.11, 0.33, 1, 3 μM) induces G2 arrest partially through topoisomerase II in A549 lung cancer cell line. Voreloxin cytotoxic activity requires DNA intercalation. However, Voreloxin (1-9 μM) does not generate significant levels of ROS. Voreloxin has potent cytotoxic activity in AML cell lines MV4-11 and HL-60, with IC50s of 95 ± 8 nM and 884 ± 114 nM, respectively. Voreloxin in combination with cytarabine shows additive or synergistic activity in acute leukemia cell lines. Voreloxin is active on the primary acute myeloid leukemia (AML) with a mean LD50 of 2.3 μM. The LD50 for voreloxin in myeloid cell lines NB4 and HL-60 is 0.59 μM ± 0.25 μM. Voreloxin causes accumulation of cells in the S and G2 phases of the cell cycle and acts on topoisomerase II.
-
In VivoVoreloxin (20 mg/kg, i.v.) alone results in 80% reduction in bone marrow cellularity of CD-1 mice by administration one dose every 4 days repeated twice (q4d ×2). voreloxin at 10 mg/kg in combination with cytarabine causes ablation of the marrow, dilation of sinusoids, and infiltration of adipocytes in mice. Voreloxin (20 mg/kg, i.v.) combined with cytarabine causes a reversible decrease in myeloid and lymphoid cells in bone marrow and peripheral blood CD-1 mice. voreloxin (10 mg/kg, q4d ×2) and cytarabine in combination causes reversible neutropenia with a more modest impact on platelets CD-1 mice.
-
SynonymsVosaroxin | SNS-595 hydrochloride
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|Topo II
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number175519-16-1
-
Formula Weight437.9
-
Molecular FormulaC18H20ClN5O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:20 mg/ml (45.67 mM)
-
SMILES[H]Cl.O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tsuzuki Y, et al. J Med Chem. 2004, 47(8), 2097-2109.
molnova catalog
related products
-
Beta-mangostin
Beta-Mangostin (β-Mangostin) is a xanthone compound with antibacterial and antimalarial activities.
-
Iberdomide
Iberdomide is a modulator of cereblon( IC50 value of 60 nM in a competitive TR-FRET assay).
-
Fluorizoline
Fluorizoline is a PHB-binding compound with anticancer and antiproliferative activity that induces apoptosis by inducing selective targeting of the BH3 protein NOXA to PHB.Fluorizoline inhibits protein synthesis and has been used in studies of leukemia.
Cart
sales@molnova.com